Krystal Biotech posted a solid 3Q with $127.3 million in VYJUVEK revenue and $1.1 billion since launch, plus completed pricing negotiations in Germany and Italy. KB113 clinical data show regression in more than 80% of Gorlin syndrome basal cell carcinoma lesions, supporting therapeutic potential. The company closed the quarter with $1.2 billion in cash and investments and authorized a $400 million share repurchase, signaling robust capital flexibility and upside potential.
Krystal Biotech's Q1 earnings of $1.83 surpassed estimates, positively reflecting its financial health. Analysts responded by increasing their price targets, with Evercore ISI raising theirs to $300 and Citigroup to $378, indicating a strong outlook despite a slight dip in share price.
FDA approved KRYS label update for Vyjuvek, expanding patient eligibility. New update enhances flexibility in managing wound dressings for patients. Real-world data supports Vyjuvek's long-term safety and efficacy. Analysts believe current valuation underestimates Vyjuvek's revenue potential. KRYS stock increased 6.01% following the label update announcement.
- Krystal Biotech (KRYS) has favorable earnings estimate revisions, potentially leading to an earnings beat. - The Most Accurate Estimate for the current quarter is higher than the Zacks Consensus Estimate. - Positive Zacks Earnings ESP and Zacks Rank #3 indicate potential positive surprise for investors. - Recent backtest shows stocks with similar indicators have returned over 28% annually. Price Impact Rating: bullish Impact Horizon Rating: short-term Type: Research Analysis